Omnicell (OMCL) Stock Valuation Check After Mixed Recent Performance Moves

Omnicell stock snapshot after recent performance moves

Omnicell (OMCL) has drawn investor attention after a mixed stretch, with the stock roughly flat over the past day, down about 12% over the past month, and up around 10% in the past 3 months.

See our latest analysis for Omnicell.

Looking beyond the recent pullback, Omnicell’s 1 year total shareholder return of 29.33% contrasts with the weaker year to date share price return of 16.19%. This suggests that earlier momentum has cooled as investors reassess growth and risk.

If Omnicell’s recent swings have you thinking about where else capital could work, this is a good moment to scan 40 healthcare AI stocks

With Omnicell trading at $37.83, alongside an indicated intrinsic discount of 31% and a sizeable gap to analyst targets, the key question is whether the recent reset leaves undervaluation on the table or whether the market is already pricing in future growth.

Most Popular Narrative: 38.3% Undervalued

With Omnicell last closing at $37.83 against a narrative fair value of $61.29, the current setup reflects a wide implied valuation gap that hinges on execution in medication management and recurring software.

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.

Read the complete narrative.

Want to see what is baked into that fair value? The narrative leans heavily on recurring revenue, richer margins, and a future earnings multiple that assumes real follow through.

Result: Fair Value of $61.29 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, that upside story still competes with tariff pressures that could squeeze margins, as well as macro or budget headwinds that slow hospital automation spending and delay cabinet upgrades.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another angle on valuation

While the narrative fair value and DCF style work suggest Omnicell is trading at a discount to future cash flow estimates, the simple P/E view points the other way. At 84.2x earnings versus 24.5x for the US Medical Equipment industry and a 31.3x peer average, and a fair ratio of 35.7x, the stock carries a rich multiple that could limit upside if expectations soften. Which lens do you trust more when the signals disagree?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this mix of upside and caution feels finely balanced, treat it as a prompt to check the data yourself and move decisively. To see exactly what investors are optimistic about right now, review the 3 key rewards

Looking for more investment ideas?

If Omnicell sits in the “maybe” bucket for you, do not stop there. Broaden your watchlist now or you risk missing the next moves elsewhere.

• Target potential bargains by scanning quality stocks trading at attractive valuations using the 44 high quality undervalued stocks
• Prioritize resilience by focusing on companies with strong finances and cleaner balance sheets through the solid balance sheet and fundamentals stocks screener (48 results)
• Spot under-the-radar opportunities before the crowd by checking the screener containing 20 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com